

Please add the following claims:

A. 35. (New) A method for treating a patient suffering from hypermotilinemia comprising administering to said patient an effective amount of a compound according to claim 1.

36. (New) A method for suppressing gastrointestinal motility in a patient suffering therefrom comprising administering to said patient an effective amount of a compound according to claim 1.

REMARKS

Claims 1-25 and 28-36 presently appear in this case. The above amendments to the specification are being made in order to correct several self-evident typographical errors. The amendments to the claims are being made in order to add new claims.


Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Favorable consideration is earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By:


Roger L. Browdy
Registration No. 25,618

RLB:wri

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

Version with markings to show changes

IN THE SPECIFICATION

A paragraph was added after the title.

Page 42, please amend Table A-8 as follows:

Table A-8

Example No.	Structural formula or chemical name
126	N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH ₂ OH
127	Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH ₂ OH
128	N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH ₂ OH
129	N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH ₂ OH
130	Phe(4-F)-N-Et-Val-N-Et-Tyr(3-tBu)-NHCH ₂ OH
131	N-Me-Phe(4-F)-N-Et-Val-N-Et-Tyr(3-tBu)-NHCH ₂ OH
132	Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH ₂ OH
133	(2S)-2-[(2S)-2-amino-3-(4-fluorophenyl)-N-methylpropanolyamino]-N-((1S)-1-[[3-(tert-butyl)-4-hydroxyphenyl]methyl]-2-morpholin-4-yl-2-oxoethyl)-3-methyl-N-methylbutanamide
134	(2S)-2-[(2S)-2-amino-3-(4-fluorophenyl)-N-methylpropanolyamino]-N-((1S)-1-[[3-(tert-butyl)-4-hydroxyphenyl]methyl]-2-[4-(methylsulfonyl)piperazinyl]-2-oxoethyl)-3-methyl-N-methylbutanamide
135	ethyl 2-[4-((2S)-2-((2S)-2-((2S)-2-amino-3-(4-fluorophenyl)-N-methylpropanolyamino)-3,N-dimethylbutanoylamino)-3-[3-(tert-butyl)-4-hydroxyphenyl] <u>propanoyl propanoly</u>)piperazinyl]acetate
136	2-[4-((2S)-2-((2S)-2-((2S)-2-amino-3-(4-fluorophenyl)-N-methylpropanolyamino)-3,N-dimethylbutanoylamino)-3-[3-(tert-butyl)-4-hydroxyphenyl] <u>propanoyl propanoly</u>)piperazinyl]acetic acid
137	Phe(4-F)-N-Me-Val-N-Pr-Tyr(3-tBu)-NH
138	Phe(4-F)-N-Me-Abu-N-Me-Tyr(3-tBu)-NH
139	Phe(4-F)-N-Me-D-Abu-N-Me-Tyr(3-tBu)-NH
140	Phe(4-F)-N-Me-Nva-N-Me-Tyr(3-tBu)-NH

Page 43, please amend Table A-9 as follows:

Table A-9

Example No.	Structural formula or chemical name
141	Phe (4-F) -N-Me-D-Nva-N-Me-Tyr (3-tBu) -NH
142	Phe (4-F) -N-Me-Ile-N-Me-Tyr (3-tBu) -NH
143	Phe (4-F) -N-Me-D-Ile-N-Me-Tyr (3-tBu) -NH
144	Phe (4-F) -N-Me-Leu-N-Me-Tyr (3-tBu) -NH
145	Phe (4-F) -N-Me-D-Leu-N-Me-Tyr (3-tBu) -NH
146	(2S)-2-[(2S)-2-amino-3-(4-fluorophenyl)-N- <u>methylpropanoylamino methylpropanolyamino</u>]-N-((1S)-2-[3-(tert-butyl)-4-hydroxyphenyl]-1-carbamoylethyl)-N-methylpent-4-enamide
147	(2R)-2-[(2S)-2-amino-3-(4-fluorophenyl)-N- <u>methylpropanoylamino methylpropanolyamino</u>]-N-((1S)-2-[3-(tert-butyl)-4-hydroxyphenyl]-1-carbamoylethyl)-N-methylpent-4-enamide
148	Phe (4-F) -N-Me-Leu (γ -Me) -N-Me-Tyr (3-tBu) -NH
149	Phe (4-F) -N-Me-D-Leu (γ -Me) -N-Me-Tyr (3-tBu) -NH
150	Phe (4-F) -N-Me-Ala (β -CF ₃) -N-Me-Tyr (3-tBu) -NH
151	Phe (4-F) -N-Me-Chg-N-Me-Tyr (3-tBu) -NH
152	Phe (4-F) -N-Me-D-Chg-N-Me-Tyr (3-tBu) -NH
153	Phe (4-F) -N-Me-Cha-N-Me-Tyr (3-tBu) -NH
154	Phe (4-F) -N-Me-D-Cha-N-Me-Tyr (3-tBu) -NH
155	Phe (4-F) -N-Me-Phe-N-Me-Tyr (3-tBu) -NH
156	Phe (4-F) -N-Me-D-Phe-N-Me-Tyr (3-tBu) -NH
157	Phe (4-F) -N-Me-Phe (4-F) -N-Me-Tyr (3-tBu) -NH
158	Phe (4-F) -N-Me-D-Phe (4-F) -N-Me-Tyr (3-tBu) -NH
159	Phe (4-F) -N-Me-Phe (4-Cl) -N-Me-Tyr (3-tBu) -NH
160	Phe (4-F) -N-Me-D-Phe (4-Cl) -N-Me-Tyr (3-tBu) -NH
161	Phe (4-F) -N-Me-Tyr-N-Me-Tyr (3-tBu) -NH
162	Phe (4-F) -N-Me-D-Tyr-N-Me-Tyr (3-tBu) -NH
163	Phe (4-F) -N-Me-Ala (β -2-thienyl) -N-Me-Tyr (3-tBu) -NH

Page 106, please amend paragraph 1 as follows:

To a solution of 2-(4-benzyloxy-3-t-butylphenyl)-1-cyanomethylethylcarbamic acid benzyl ester (1.38 g, 3.03 mmol) in DMSO (24 ml), potassium carbonate (1.59 g) and 30% hydrogen peroxide (4.0 ml) were added under cooling with ice. After stirring at room temperature for 2 hours, the reaction mixture was mixed with water; the thus formed precipitates were collected by filtration to give 2-(4-benzyloxy-3-t-butylphenyl)-1-carbamidemethylethylcarbamic acid benzyl ester.

Page 257, please amend Table E-7 as follows:

Table E-7

Intermediate T14

(2S)-3-[3-(tert-butyl)-4-hydroxyphenyl]-2-(methyamino)-1-[4-(methylsulfonyl)piperazinyl piperazineyl]propane-1-one

Run	Time (min)	Temp (°C)	Flow Rate (mL/min)	Pressure (bar)	Wavelength (nm)	Intensity (a.u.)	Retention Time (min)	Peak Area (a.u.)
1	10	40	0.5	10	254	1000	10.5	1000
Sample 1								
2	10	40	0.5	10	254	1000	10.5	1000
Sample 2								
3	10	40	0.5	10	254	1000	10.5	1000
Sample 3								
4	10	40	0.5	10	254	1000	10.5	1000
Sample 4								
5	10	40	0.5	10	254	1000	10.5	1000
Sample 5								
6	10	40	0.5	10	254	1000	10.5	1000
Sample 6								
7	10	40	0.5	10	254	1000	10.5	1000
Sample 7								
8	10	40	0.5	10	254	1000	10.5	1000
Sample 8								
9	10	40	0.5	10	254	1000	10.5	1000
Sample 9								
10	10	40	0.5	10	254	1000	10.5	1000
Sample 10								

IN THE CLAIMS

Now claims 35 and 36 were added.